8-K: Achieve Life Sciences Appoints Mark K. Oki as New Chief Financial Officer

Achieve Life Sciences has appointed Mark K. Oki as its new Chief Financial Officer, effective December 5, 2024.

Summary

• Achieve Life Sciences has appointed Mark K. Oki as their new Chief Financial Officer, effective December 5, 2024.
• Mr. Oki's employment agreement includes an annual base salary of $450,000.
• He is eligible for an annual discretionary bonus of up to 40% of his base salary.
• Mr. Oki will receive an option to purchase 72,000 shares of the company's common stock, vesting over three years.
• He will also receive 168,000 performance-based restricted stock units.
• The agreement includes severance terms in case of termination without cause or resignation for good reason, including up to 24 months of salary and bonus in the event of a change in control.

Sentiment

Score: 7

Explanation: The document reflects a positive development with the appointment of a new CFO, but it is a standard business operation and does not indicate any significant change in the company's outlook.

Positives

• The appointment of Mark K. Oki brings a seasoned financial executive with extensive experience in the pharmaceutical industry.
• The compensation package for the new CFO includes a competitive base salary, bonus potential, and equity incentives.
• The severance package provides security for the CFO in case of termination without cause or resignation for good reason.

Risks

• The company will incur additional costs related to the new CFO's compensation package.
• The performance-based restricted stock units are subject to the achievement of performance objectives set by the Board, which may not be met.

Future Outlook

The company has not provided any specific forward-looking statements in this document, but the appointment of a new CFO is a key step in the company's ongoing operations.

Management Comments

• The Board of Directors of the Company appointed Mark K. Oki as the Company's Chief Financial Officer and principal financial officer.

Industry Context

The appointment of a new CFO is a common occurrence in the pharmaceutical industry, especially for companies in a growth phase. Mr. Oki's experience at other pharmaceutical companies suggests that Achieve Life Sciences is looking to strengthen its financial leadership.

Comparison to Industry Standards

• The base salary of $450,000 for a CFO is within the typical range for a company of this size in the pharmaceutical industry.
• The equity incentives, including stock options and restricted stock units, are also standard practice for attracting and retaining top executive talent.
• The severance package is also in line with industry standards, providing a safety net for the executive in case of termination.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CFO with extensive experience as a positive step for the company.
• Employees may see this as a sign of stability and growth within the company.
• Creditors may view this as a positive sign of financial management.

Next Steps

• The employment agreement will be filed as an exhibit to the company's Annual Report on Form 10-K for the fiscal year ending December 31, 2024.

Key Dates

Keywords

Chief Financial Officer, CFO, executive appointment, pharmaceutical, compensation, stock options, severance, Achieve Life Sciences